Mon, Jan 26, 2015, 6:27 AM EST - U.S. Markets open in 3 hrs 3 mins


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • insmhistorian insmhistorian Jul 23, 2014 2:52 PM Flag

    I'm sorry...... post about my thoughts on Insmed/Roche/PUMA was deleted twice today. Since there must not be anything of interest there, I apologize for wasting the space of this board. Hope everyone is doing well.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Do you mean this one?

      -- Dave


      This is a little off-topic from Arikayce, but it is something that made me think.
      With all of the talk about PUMA yesterday/today, I read terms like breast cancer,
      Roche, Herceptin, and it got things rolling around my head. So, I looked
      back into the Insmed archives and found the following information from 2003.
      As much as I dislike Roche/Genentech (LOL) might they be interested in
      relationship with Insmed (separate from iPlex)).....again, LOL

      RICHMOND, Va.--(BUSINESS WIRE)--Dec. 3, 2003--Insmed Incorporated (Nasdaq-NMS: INSM) (Nasdaq: INSM) reported today that data from recent studies of the Company's proprietary anti-cancer compound, recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3), will be presented at The 26th Annual San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. Gonzalez Convention Center, San Antonio, Texas, December 3 - 6.

      These studies conducted in the laboratory of Dr. Brian Leyland-Jones of McGill University were designed to explore the ability of rhIGFBP-3 to sensitize breast cancer cells to Herceptin® (Trastuzumab).

      The results of this study, published in the abstract titled, "Recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3) as a potential therapeutic agent for the treatment of Herceptin-resistant breast cancer", demonstrated the following:

      1. In Herceptin resistant breast carcinoma cells there was an increased level of insulin-like growth factor receptor.

      2. rhIGFBP-3 caused dose dependent inhibition of Herceptin resistant breast carcinoma growth.

      3. rhIGFBP-3 in combination with Herceptin caused a dose dependent increase in sensitivity of breast carcinoma cells to Herceptin.

      For reprints, please contact, Baxter Phillips, at 804.565.3041 or bphillips@insmed.c

    • That tells me that they`ll have to pry my shares out of my cold dead hands,because they`re not for sale until we see the 300.00 level at a minimum.

      Sentiment: Strong Buy

14.89+0.3000(+2.06%)Jan 23 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Infinera Corporation
NASDAQFri, Jan 23, 2015 4:00 PM EST
Five Prime Therapeutics, Inc.
NASDAQFri, Jan 23, 2015 4:00 PM EST